Bezafibrate for X-Linked Adrenoleukodystrophy

Marc Engelen1,3, Luc Tran2, Rob Ofman2, Josephine Brennecke2, Ann B. Moser4, Inge M. E. Dijkstra2, Ronald J. A. Wanders2, Bwee Tien Poll-The1,3, Stephan Kemp2,3*

1 Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 2 Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 3 Department of Pediatric Neurology/Emma Children’s Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 4 Department of Neurogenetics, Kennedy Krieger Institute, Baltimore, Maryland, United States of America

Abstract

X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene and is characterized by impaired β-oxidation of very-long-chain fatty acids (VLCFA) and subsequent VLCFA accumulation in tissues. In adulthood X-ALD most commonly manifests as a gradually progressive myelopathy, (adrenomyeloneuropathy; AMN) without any curative or disease modifying treatments. We recently showed that bezafibrate (BF), a drug used for the treatment of hyperlipidaemia, reduces VLCFA accumulation in X-ALD fibroblasts by inhibiting ELOVL1, an enzyme involved in the VLCFA synthesis. Therefore designed a proof-of-principal clinical trial to determine whether BF reduces VLCFA levels in plasma and lymphocytes of X-ALD patients. Ten males with AMN were treated with BF for 12 weeks at a dose of 400 mg daily, followed by 12 weeks of 800 mg daily. Every 4 weeks patients were evaluated for side effects and blood samples were taken for analysis. Adherence was good as indicated by a clear reduction in triglycerides. There was no reduction in VLCFA in either plasma or lymphocytes. Plasma levels of BF did not exceed 25 μmol/L. We concluded that BF, at least in the dose given, is unable to lower VLCFA levels in plasma or lymphocytes in X-ALD patients. It is unclear whether this is due to the low levels of BF reached in plasma. Our future work is aimed at the identification of highly-specific inhibitors of ELOVL1 that act at much lower concentrations than BF and are well tolerated. BF appears to have no therapeutic utility in X-ALD.

Trial Registration: ClinicalTrials.gov NCT01165060

Methods

The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1. The BEZA trial study protocol was approved by the Institutional Review Board (Medisch Ethische Toetsings Commissie) of the Academic Medical Center. The trial is registered at clinicaltrials.gov (NCT01165060). Adult men with biochemically and genetically proven X-ALD without contraindications for the use of BF were eligible for inclusion. All participating patients were evaluated at baseline for eligibility and received trial medication after written informed consent was obtained. They were evaluated at intervals of 4 weeks until the end of the trial at 24 weeks. The initial dose of BF was 400 mg per day, which was subsequently increased to 800 mg per day at week 12 (Figure 1). At each visit side effects were monitored, a general physical examination including weight was performed and blood samples taken. Blood samples were taken in the morning after an overnight fast before the first medication dose. Blood samples were analyzed at the laboratory for clinical chemistry for routine laboratory tests. VLCFA and BF levels were analyzed as previously described [6,7]. Lysophosphatidylcholine-C26:0 (C26:0 lysPC) was analyzed in bloodspots [8].
Results

Ten males with AMN participated in the trial. No side effects that necessitated discontinuation of the trial medication occurred. Body weight was unchanged (Table 1). There was a clear reduction in plasma triglycerides (1.34 mmol/L to 0.71 mmol/L at BF 400 mg and 0.71 mmol/L at BF 800 mg), and to a lesser extent a decrease in total cholesterol and LDL-cholesterol. There was also an increase in HDL-cholesterol (Table 1). These are known effects of BF and confirm patient adherence. There was no consistent reduction in C26:0 in plasma or lymphocytes, neither at 400 nor at 800 mg BF per day (Table 1). We observed an increase in plasma C22:0 and C24:0 at a dose of 800 mg BF per day. The amount of C26:0 lysoPC was unchanged in blood spots after 24 weeks of treatment with BF. The plasma level of BF did not exceed 25 μmol/L at the highest dose of 800 mg BF per day.

Discussion

The pathophysiology of X-ALD is not well understood, although it seems likely that accumulation of VLCFA is toxic and related to neurodegeneration [9]. Therefore drugs that reduce the level of VLCFA might be effective in halting or slowing progression of the disease.

Recently, we showed that it is possible to reduce VLCFA in fibroblasts from X-ALD patients by inhibiting the synthesis of VLCFA by the enzyme ELOVL1 [3]. We later showed that this can also be accomplished by incubating fibroblasts from X-ALD patients with BF [4].

BF is a drug that has been in use for decades for the treatment of hypertriglyceridaemia and has an excellent safety profile [5]. Therefore we decided to initiate this small scale proof of principle clinical trial to investigate whether BF reduces VLCFA in plasma and lymphocytes of X-ALD patients. In a previous clinical trial to investigate whether BF reduces VLCFA in plasma C22:0 and C24:0 at a dose of 800 mg BF per day. The amount of C26:0 lysoPC was unchanged in blood spots after 24 weeks of treatment with BF. The plasma level of BF did not exceed 25 μmol/L at the highest dose of 800 mg BF per day.

Table 1. Summary of the different parameters measured at the indicated time point in the trial.

| Parameter                  | Baseline | BF 400 mg | BF 800 mg |
|----------------------------|----------|-----------|-----------|
| Total cholesterol (mmol/L) | 5.57±1.42| 4.80±0.88*| 4.85±0.84*|
| LDL (mmol/L)               | 3.67±1.17| 2.93±0.80**| 2.90±0.73*|
| HDL (mmol/L)               | 1.39±0.25| 1.57±0.25***| 1.64±0.26***|
| TG (mmol/L)                | 1.34±0.79| 0.70±0.31**| 0.71±0.22* |
| C22:0 (μmol/L)             | 43.32±9.25| 45.37±8.12| 55.02±9.74**|
| C24:0 (μmol/L)             | 62.56±11.68| 64.08±11.78| 82.62±12.50**|
| C26:0 (μmol/L)             | 3.26±0.96| 2.56±0.50**| 2.99±0.49|
| C26:0/C22:0 ratio          | 0.075±0.015| 0.058±0.012| 0.056±0.012***|
| Bezafibrate (μmol/L)       | n.d.     | n.d.      | 10.1±6.7  |

Values are mean ± the standard deviation. Statistically significant differences from the baseline value are indicated.

*p<0.05, **p<0.01, ***p<0.001. n.d. = not determined.
exceed 25 μmol/L with an average of 10 μmol/L (Table 1). These levels are not peak levels, but rather residual plasma levels. It is unlikely that concentrations even approaching 400 μmol/L were reached. This may explain the lack of in vivo efficacy of BF on our outcome parameters. To achieve the effect of VLCFA reduction, significantly higher BF concentrations are necessary as compared to concentrations indicated for reduction of TG.

Future research will be focused on the identification of specific inhibitors of ELOVL1 that act at much lower concentrations than BF and are well-tolerated. In conclusion, BF appears to have no therapeutic utility in X-ALD.

References

1. Moser HW, Mahmood A, Raymond GV (2007) X-linked adrenoleukodystrophy. Nat Clin Pract Neurol 3: 140–151.
2. Mosser J, Douar AM, Sarde CO, Kioochi P, Feil R, et al. (1993) Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 361: 726–730.
3. Ofman R, Dijkstra IM, van Roermund CW, Burger N, Turkenburg M, et al. (2010) The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO Mol Med 2: 90–97.
4. Engelen M, Schackmann MJ, Ofman R, Sanders RJ, Dijkstra IM, et al. (2012) Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation. J Inherit Metab Dis. 10.1007/s10545-012-9471-4 [doi].
5. Miller DB, Spence JD (1998) Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34: 155–162.
6. Valianpour F, Selhorst J, van Lint LE, van Gennip AH, Wanders RJ, et al. (2003) Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry. Mol Genet Metab 79: 189–196.
7. Masnatta LD, Cuniberti LA, Rey RH, Werba JP (1996) Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 687: 437–442.
8. Hubbard WC, Moser AB, Liu AC, Jones RO, Steinberg SJ, et al. (2009) Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 97: 212–220.
9. Kemp S, Berger J, Aubourg P (2012) X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta. 10.1016/j.bbadis.2012.03.012 [doi].
10. Engelen M, Ofman R, Dijkgraaf MGW, Hijzen M, van der Wardt LA, et al. (2010) Lovastatin in X-Linked Adrenoleukodystrophy. N Engl J Med 362: 276–277.